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Alterations of the customary 28-day combined contraceptive regimen can be used to 
reduce or eliminate monthly bleeding.  
 
ABSTRACT 
Many women have medical indications for menstrual suppression or a personal 
preference to reduce or eliminate monthly bleeding, which can be achieved with 
extended and continuous regimens of combined estrogen and progestin contraceptives. 
Combined contraceptives are traditionally administered in a 28-day cycle with 21 days 
of a contraceptive pill, vaginal ring, or transdermal patch followed by a hormone-free 
interval that is usually 7 days. During the hormone-free interval, women either take a 
placebo pill or do not use their combined contraceptive method. Hormone-related 
symptoms are higher during the hormone-free interval than the days when the 
contraceptive is used. Alterations of the standard 28-day cyclic regimen for menstrual 
suppression include decreasing the frequency of the hormone-free interval, thus 
extending the time between withdrawal bleeding episodes (extended use), and 
eliminating the hormone-free interval altogether (continuous use). This article reviews 
menstrual suppression indications and physiology. Research demonstrating that the 
effectiveness, safety, and side effects of oral, vaginal, and transdermal extended and 
continuous regimens are comparable to cyclic regimens is summarized. Findings from 
studies of women’s and health care providers’ attitudes toward menstrual suppression 
are also reviewed. Important topics to include in evidence-based counseling for 
extended and continuous combined contraceptive use are presented. 
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INTRODUCTION 
Frequent menstruation is a relatively new phenomenon. It has been estimated that 
modern women experience 3 times the number of menstrual cycles per lifetime than did 
pre-agricultural women.1,2 Approximately 450 menses can be anticipated in modern 
Western women due to earlier menarche, later childbearing, lower parity, shorter 
periods of breastfeeding, and later menopause.2 
Monthly menstruation is perceived by some as a “natural” state necessary for 
cleansing the system. Monthly menses may also be seen as a symbol of femininity, 
fertility, and youth. Practically speaking, monthly menses is a sure sign that a woman is 
not pregnant and provides reassurance of fertility potential and reproductive health. 
 The customary 21/7 cycle, which includes 21 days of active estrogen and 
progestin pills followed by 7 days of placebo pills, originated with John Rock and 
Gregory Pincus, co-inventors of the first oral contraceptive pill.3 Although Pincus stated 
as early as 1958 “a cycle of any desired length could presumably be produced,”3 the 
end product was a 28-day cycle with a placebo week during which bleeding occurs. The 
placebo week technically induces withdrawal bleeding from the lack of exogenous 
hormones though this bleeding is commonly referred to as menses.  
There was no scientific evidence that the 21/7 cycle was best; rather, mimicking 
the native menstrual cycle was intended to increase acceptance of combined oral 
contraceptives. The high hormone doses in early pills could cause significant 
symptoms, many of which were similar to pregnancy, such as nausea, vomiting, and 
breast tenderness. Monthly bleeding reassured women they were not pregnant and 
alleviated concerns about long-term adverse effects of the pill.4 Rock and Pincus also 
hoped the monthly cycle of the pill would lead to the Pope to approve its use by 
Catholics, which did not come to fruition.3  
Cyclic, Extended, and Continuous Combined Contraceptive Regimens 
Cyclic combined contraceptive regimens are the traditional 28-day cycles with 21 days 
of a combined estrogen and progestin contraceptive pill, vaginal ring, or transdermal 
patch followed by a hormone-free interval that is usually 7 days. During the hormone-
free interval, women either take a placebo pill or do not use their combined 
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frequently than every month, usually 3 to 4 times a year. Continuous regimens omit the 
hormone-free interval entirely.  
Extended and continuous regimens have been reported in the literature since the 
1970s,5 and clinicians have long advised women they could “bicycle” or “tricycle” pills by 
taking multiple packages in a row without a hormone-free interval. The US Food and 
Drug Administration (FDA) first approved dedicated products for extended and 
continuous regimens in 2003 (Seasonale) and 2007 (Lybrel) respectively.6 Combined 
oral contraceptives approved and packaged for extended and continuous use are listed 
in Table 1. Other combined oral contraceptives, the contraceptive vaginal ring, and the 
transdermal contraceptive patch can also be used off-label in extended and continuous 
regimens. Studies have shown that extended and continuous combined contraceptive 
regimens are as effective at preventing pregnancy as cyclic regimens, and there is 
some evidence to suggest extended and continuous contraceptive regimens may be 
more effective at preventing pregnancy than 21/7 regimens by blunting the pituitary-
ovarian axis response during the hormone-free interval and reducing or eliminating 
breakthrough ovulation.7-9  
 
<<FOR TYPESETTER, PLEASE INSERT TABLE 1 ABOUT HERE>> 
 
Indications for Menstrual Suppression 
There are many indications for menstrual suppression in women and adolescents.4,10 
Menses-related conditions such as dysmenorrhea, menorrhagia, abnormal uterine 
bleeding, premenstrual syndrome, premenstrual dysphoric disorder, and menstrual 
migraines, can be treated with extended or continuous regimens. Certain medical 
conditions, such as endometriosis, anemia, bleeding disorders, and developmental 
delay, are also reasons for frequency reduction or elimination of menses. Other 
indications include relief of perimenopausal symptoms, convenience, travel (eg, 
honeymoons, vacations, business meetings), and military deployment. Last, and 
importantly, menstrual suppression is indicated for women whose preference is not to 
menstruate monthly.  
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It is important for clinicians and women to understand why it is safe to reduce or 
eliminate menses with extended or continuous use of combined contraceptives when 
oligomenorrhea and amenorrhea are considered pathologic findings that warrant 
evaluation and possibly treatment. Many women who infrequently or never menstruate 
have an interruption of the hypothalamic-pituitary-ovarian axis that results in 
anovulation. Conditions that can cause anovulation include polycystic ovary syndrome, 
hyperthyroidism or hypothyroidism, uncontrolled diabetes mellitus, eating disorders, 
hyperprolactinemia, medications (eg, antiseizure drugs, antipsychotics), and being at 
either end of the reproductive years (ie, postmenarche, perimenopause).11 With 
persistent anovulation, endometrial hyperplasia can develop because the proliferation of 
the endometrium that occurs during the follicular phase is not opposed by the 
progesterone that is normally produced in the luteal phase. However, when combined 
contraceptives are used, the endometrium is atrophic so hyperplasia does not occur. 
The reduction or elimination of menses with extended or continuous use of combined 
contraceptives is an expected outcome of exogenous hormone administration, rather 
than an indication of a pathologic process that is causing anovulation and potential 
health risks. 
 
EFFECTIVENESS, SAFETY, AND SIDE EFFECTS OF CYCLIC, EXTENDED, AND 
CONTINUOUS REGIMENS OF COMBINED ORAL CONTRACEPTIVES 
Withdrawal Symptoms with the Cyclic Regimen 
In 2000, Sulak et al published a landmark study that investigated hormone-related 
symptoms during the active-pill and hormone-free intervals in 262 women taking 
combined oral contraceptives12. Women who had no prior use, were restarting use, or 
had been taking combined oral contraceptives for 12 months or longer participated in 
the study. All participants used a daily diary to record symptoms. Pelvic pain (70% vs 
21%, P<.001), headaches (70% vs 53%, P<.001), breast tenderness (38% vs 16%, 
P<.001), and bloating or swelling (58% vs 19%, P<.001) were all significantly worse 
during the 7-day hormone-free interval when compared with the 21-day active-pill 
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hormone-free interval (69% vs 43 %, P<.001).12 These hormone withdrawal symptoms 
can be severe in some women.13  
Extended Regimens 
In 2001, Miller et al published a 2-year study comparing cyclic 28-day versus extended 
49-day regimens.14 Ninety women were randomly assigned to a combined oral 
contraceptive (30 mcg ethinyl estradiol + 300 mcg norgestrel) with either 21/7 or 42/7 
cycles over 4 84-day reference periods; 53 women completed the study. During the 
study, women kept diaries on bleeding, pill taking, and symptoms. The mean number of 
bleeding days was significantly lower with the extended regimen compared to the cyclic 
regimen (P=<.001 for first and fourth reference periods, P=.05 for second reference 
period, P=.03 for third reference period). The mean number of spotting days was similar 
for both regimens (P>.05 for all 4 reference periods). Overall, there were no significant 
differences in amenorrhea, frequent menses, or prolonged menses. Days of hygiene 
product use over the year of the study were significantly lower for women on the 
extended regimen (28-day=53.5, 49-day=27.3, P<.001). Women in the 49-day group 
had significantly lower median headache symptom scores than women in the 28-day 
group. Breast tenderness, cramping, weight, and method satisfaction scores did not 
differ significantly.14  
 Another randomized controlled trial compared the safety and efficacy of 4 91-day 
cycles with 13 28-day cycles in 682 women of whom 432 completed the study.15 The 
extended-cycle regimen consisted of 84 continuous days of the combined oral 
contraceptive (30 mcg ethinyl estradiol + 150 mcg levonorgestrel) followed by a 7-day 
placebo interval. Over the course of the study, participants used an electronic diary to 
report symptoms and pill taking. In addition, endometrial biopsies were performed on a 
subset of patients to assess endometrial changes. A total of 7 patients became 
pregnant during the study: 4 of 456 (0.9%) in the 91-day cycle group and 3 of 226 
(1.3%) in the 28-day cycle group. With each successive cycle, days of breakthrough 
bleeding as well as the onset and duration of breakthrough bleeding decreased in the 
91-day cycle group. By the last extended cycle (cycle 4), breakthrough bleeding was 
comparable between the 91-day cycle group and the 28-day cycle group. The median 
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subset (n=50) of the women who received up to 4 cycles of the 91-day cycle had 
endometrial biopsies before and after therapy.16,17 No hyperplasia or significant 
pathology was noted.16 The endometrium quickly reverted to normal cyclic changes 
after discontinuation of the extended regimen suggesting extended use of combined 
contraceptives has no adverse effect on the endometrium.17  
 An open-label, single-treatment study of 1249 women reported similar results for 
an extended 91-day cycle (20 mcg ethinyl estradiol + 100 mcg levonorgestrel) utilizing 7 
low-dose ethinyl estradiol pills (10 mcg each) rather than a hormone-free interval.18 Use 
of low-dose estrogen pills in lieu of a hormone-free interval has also been shown to 
improve the bleeding profile, decrease the number of developing follicles, and possibly 
reduce headaches compared to the 91-day cycle utilizing a hormone-free 7-day 
interval.19,20  
While most studies of extended regimens have been 2 years or shorter, Davis et 
al followed women who had been in 1-year continuous regimen trials16,21 for 4 years 
(N=320, n=85 for full 4 years).22 The incidence of commonly reported adverse effects 
(eg, headache, metrorrhagia, dysmenorrhea) was not significantly higher during the 
extended study compared to the initial trials. Complete blood count, serum chemistry, 
lipid profile, and urinalysis values remained the same or only changed minimally. Blood 
pressure was stable. Median rates of unscheduled bleeding or spotting (outside of the 
hormone-free interval) declined over the duration of the study.22 
Multiple other studies have confirmed extended regimens of combined oral 
contraceptives improve hormone-withdrawal symptoms and are well tolerated and 
safe.21,23-30 An analysis of 1736 women using a 91-day regimen (20 mcg ethinyl 
estradiol + 100 mcg levonorgestrel) found contraceptive efficacy was not reduced in 
women who were overweight or obese.31 In addition, a pharmacokinetic study confirmed 
that extended use of ethinyl estradiol and levonorgestrel does not result in additional 
accumulation of these hormones in the body compared to cyclic regimens.32 Other 
studies have demonstrated lipid profiles, hemostasis variables, thyroid hormones, and 
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In 2003, Kwiecien et al published a trial in which 32 women were randomized to 168 
days without a pill-free interval (continuous) or 6 28-day cycles (cyclic) using a 
combined oral contraceptive (20 mcg ethinyl estradiol + 100 mcg levonorgestrel); 28 
women completed the study.36 A daily diary was maintained by participants evaluating 
adverse side effects of headache, bloating, breast tenderness, nausea, depression, 
premenstrual syndrome, and menstrual pain. The diary also tracked bleeding events in 
3 categories: none, spotting, or required sanitary protection. The women on the 
continuous regimen had fewer total bleeding days than the women in the 28-day cycle 
group (25.9 vs. 34.9); however, this result was not statistically significant. Women on 
the continuous regimen reported significantly fewer bleeding days that required 
protection than women on the cyclic regimen (18.4 vs. 33.8, P < .01). Both groups 
reported a high level of satisfaction with side effects and bleeding. Overall, women in 
the continuous group reported fewer days of bloating (0.7 vs. 11.1, P = .04) and 
menstrual pain (1.9 vs. 13.3, P < 0.01) than the cyclic group. Other side effects were 
reported infrequently with no significant difference between groups. The women on the 
continuous regimen underwent endometrial stripe measurements, which were all within 
normal range. No endometrial biopsies were needed.36   
 Later in 2003, Miller et al reported a study in which 79 women were randomized 
to 28-day cycles or continuous use of a combined oral contraceptive (20 mcg ethinyl 
estradiol + 100 mcg levonorgestrel) for 12 cycles; 60 women completed the study.37 The 
2 groups did not have a significant difference in total spotting days, and the median 
number of spotting days in the continuous group declined over time (9.0 in cycles 1-3 vs 
1.5 in cycles 10-12) while there was little change in the cyclic group (6.0 in cycles 1-3 vs 
5.0 in cycles 10-12). Weight, hemoglobin, and diastolic blood pressure did not differ 
significantly between the two groups at the study’s completion, but the continuous group 
had a slightly lower systolic blood pressure than the cyclic group (107.9 vs. 115.6, 
P=.02). No significant differences were found in method satisfaction scores and 
reported breast tenderness or nausea.37 
 Since those trials, multiple other studies have found continuous combined oral 
contraceptive regimens are effective for preventing pregnancy and hormone-withdrawal 
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after discontinuation is rapid.48,49 Continuous regimens have been found to have similar 
effects on lipids, carbohydrates, and coagulation factors as cyclic 28-day regimens.50 
 
VAGINAL AND TRANSDERMAL OPTIONS FOR EXTENDED AND CONTINUOUS 
REGIMENS 
Contraceptive vaginal ring  
The etonogestrel/ethinyl estradiol contraceptive vaginal ring (NuvaRing) was approved 
by the FDA in 2001 and is worn for 3 weeks of continuous use followed by 1 ring-free 
week during which withdrawal bleeding occurs. In 2005, Miller et al published a trial in 
which 429 women were randomized to a 28-day (21/7), 49-day (42/7), 91-day (84/7) or 
364-day cycle of the vaginal ring; 289 women completed the entire year of the study.51 
Although all 4 regimens were acceptable to women, higher rates of study completion 
were reported for the shorter cycles (77% for 28-day cycle, 72% for 49-day cycle, 62% 
for 91-day cycle, 59% for 364-day cycle). Women who had the longer cycles had fewer 
total bleeding days but more spotting days (defined as bleeding requiring 1 or less pad 
or tampon for the day) than women with shorter cycles. In another study in which 62 
women completed one year of 91-day cycles, the total number of scheduled and 
unscheduled bleeding days decreased over the course of the study.52 
One trial assessed continuous use of the vaginal ring in 65 women who 
completed 6 months of use.53 Participants changed rings monthly based on evidence 
from a pharmacokinetic study that the ring is effective for 35 days.54 One group was 
advised that if they had breakthrough bleeding, they should to remove the ring for 4 
days then reinsert it. The other group was instructed to continuously use the ring with no 
ring-free days. Women following the 4-day ring-free protocol had a greater proportion of 
days without breakthrough bleeding than women who had no ring-free days (95% vs 
89%, P=.016).  
Extended use of the vaginal ring does not change blood pressure significantly.55 
The vaginal ring has been shown to have no effect on carbohydrate metabolism in both 
cyclic and extended regimens and is therefore safe and effective for use in women with 
diabetes.56,57 Lipid metabolism and lipoprotein levels were similar in women using 84/7 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript 
Transdermal contraceptive patch  
The norelgestromin/ethinyl estradiol transdermal contraceptive patch (Ortho Evra) was 
approved for contraceptive use in the United States in 2001. The cyclic patch regimen 
consists of 3 weekly patch applications followed by a patch-free week when withdrawal 
bleeding occurs. A randomized trial of the transdermal contraceptive patch in 239 
women compared an 84/7 extended regimen to the approved 21/7 regimen.59 The 
extended regimen consisted of weekly patch application for 12 consecutive weeks 
followed by a patch-free week. Overall, women were very satisfied in both the extended 
and cyclic use groups, and the difference in reported adverse events was not 
statistically significant. The women in the extended regimen group had fewer median 
bleeding days than did the women in the cyclic use group (6 vs 14, P<.001). Similarly, 
bleeding and spotting episodes were also reduced in the women in the extended 
regimen group (2 vs 3, P<.001). There was no significant difference in the number of 
bleeding or spotting days between the 2 groups (14 vs 16, P=.407).59  
 
ATTITUDES OF WOMEN AND HEALTH CARE PROVIDERS TOWARD MENSTUAL 
SUPRESSION 
Two national surveys of women aged 18 to 40 years were conducted by the Association 
of Reproductive Health Professionals (ARHP) in 2003 prior to approval of a dedicated 
product for extended or continuous regimens (N=1470)60,61 and in 2005 (N=1021).62 
Few women reported they enjoy their menses in some way (16% in 2003 vs 8% in 
2005). The majority of women viewed menses as something they just have to put up 
with (75% in 2003 vs 77% in 2005). In 2003, half of women believed it is necessary to 
have a monthly menses; one-third disagreed or strongly disagreed. When asked how 
often they would menstruate if they had a choice, the largest proportion chose never 
(32% in 2003 vs 40% in 2005). Less than one-quarter (22% in 2003 and 2005) chose 
monthly. Most women had not heard of menstrual suppression (73% in 2003 vs 55% in 
2005). The participants in the 2 studies were not the same thus the results cannot be 
directly compared, but the findings suggest increased awareness of menstrual 
suppression. Concerns about menstrual suppression in the 2005 survey included long-
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(66%), that it could affect future fertility (58%), and that it would be too expensive 
(57%).62  
 In a study of 100 female college students, 89% had heard of menstrual 
suppression.63 Primary sources of information about menstrual suppression were media 
(64%), physicians (18%), and friends (16%). Only one-third (33%) of participants were 
willing to suppress their menses, but two-thirds (68%) said they would be willing if there 
were no side effects. Interestingly, women who reported positive menstrual cycle-
related changes were more willing to suppress menstruation than women who did not 
report positive changes.63  
 The 2003 ARHP survey also had 512 health care provider participants, the 
majority of whom were nurse practitioners (76%).60,61 Only 7% of respondents felt 
monthly menstruation was physically necessary. Most of the respondents had heard 
about menstrual suppression with extended combined oral contraceptive regimens 
(81% of health care providers vs 27% of women), and half (52%) had prescribed 
extended regimens. Issues that were rated as extremely important influences on the 
decision to prescribe extended regimens included long-term health effects (91%), future 
fertility (86%), side effects (83%), and cost (42%). 
A 2004 survey was conducted with physicians who care for adolescents (N=222); 
55% of respondents were pediatricians and 34% were gynecologists.64 The majority of 
the physicians reported prescribing extended regimens of combined hormonal 
contraceptives (90%). Patient preferences to induce amenorrhea for a specific event 
(82%) or have fewer menses (72%) were more common reasons for prescribing 
extended regimens than medical indications (eg, menorrhagia 68%, dysmenorrhea 
65%, endometriosis 62%).64 
A 2005 survey assessed the extended regimen attitudes, knowledge, and 
prescribing habits of 211 physicians in Oregon; 44% were obstetrician-gynecologists 
and 56% were family medicine physicians.65 Three-quarters of the physicians reported 
prescribing extended regimens of combined oral contraceptives often (23.5%) or 
sometimes (50.5%). Most respondents disagreed monthly withdrawal bleeds are 
essential for women on cyclic regimens (mean 1.47 on 5-point Likert scale: 1=strongly 
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Two surveys of a variety of health care providers, including physicians, nurse 
practitioners, nurse-midwives, and physician assistants were conducted in 2004 
(N=551)66 and 2008 (N=799).67 The goal of the studies was to determine attitudes and 
prescribing preferences of providers regarding extended regimens of combined oral 
contraceptives. Most respondents had prescribed extended combined oral 
contraceptive regimens in their practices (82% in 2004 vs 92% in 2008). Those who 
prescribed extended regimens were asked if they did so frequently (29% in 2004 vs 
54% in 2008), occasionally (45% in 2004 vs 31% in 2008), or rarely (24% in 2004 vs 7% 
in 2008). A minority of participants felt monthly bleeding on a cyclic regimen is 
necessary and has health benefits (12% in 2004 vs 9% in 2008). While the participants 
in the 2 studies were not the same and thus cannot be directly compared, these 
differences in prescribing over time suggest increasing acceptance of novel 
contraceptive prescribing regimens in the United States.66,67 
 
EVIDENCE-BASED COUNSELING FOR EXTENDED AND CONTINUOUS 
CONTRACEPTIVE REGIMENS 
Women need to understand the menstrual cycle as well as the mechanisms of action, 
safety, advantages, and disadvantages of contraceptive methods. This information may 
be particularly important for women to feel secure with regimens other than the 
customary 21/7 cycle. A list of important topics when counseling women about extended 
and continuous use of combined contraceptives is provided in Box 1. 
 
<<FOR TYPESETTER: PLEASE INSERT BOX 1 ABOUT HERE>> 
 
Safety 
Dozens of studies that have in total included thousands of participants have confirmed 
the safety of extended and continuous combined contraceptive regimens.14-53, 55-59 
Studies have documented no harmful effects on the uterus or endometrium. Blood 
pressure measurements and laboratory findings were not different between groups of 
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after extended or continuous hormonal regimens has been found to be the same as 
return to fertility after cyclic regimens.   
Advantages  
Many menstrual-related and medical conditions can be alleviated by extended and 
continuous regimens. Side effects associated with combined contraceptives tend to 
occur during the hormone-free interval. Use of extended and continuous regimens can 
reduce or eliminate the hormone-free interval and decrease side effects such as 
bloating, headaches, and breast tenderness. The cost of hygiene products is also 
reduced, and women’s lives are less interrupted by menses. 
Disadvantages  
Although total bleeding days are reduced with postponement or elimination of 
withdrawal bleeding in extended and continuous regimens, the number of spotting days 
often increases. This irregular bleeding will usually decrease with time as the body 
adjusts to a new hormone balance. It may also be helpful to take a 3 to 4-day hormone-
free interval if breakthrough bleeding persists.53,68,69 There is a need to remember a new 
schedule such as when to take pills or change the ring or patch. This is especially true 
for off-label use because product packaging will not include instructions for extended or 
continuous regimens. Women who have an unintended pregnancy while using an 
extended or continuous regimen may find it more difficult to detect early pregnancy 
because they do not bleed monthly so cannot use missed menses as a sign of 
pregnancy. Despite menstrual suppression, other symptoms of pregnancy (eg, breast 
tenderness, nausea, fatigue) will still be present. If a woman is particularly concerned 
about pregnancy, a pregnancy test should be performed. Last, some extended or 
continuous regimens may be more costly, and insurance may not cover extra pill packs, 
rings, or patches.  
 
CONCLUSION 
Given the evidence that most combined contraceptive side effects occur during 
hormone-free intervals and that there is no medical indication for periodic withdrawal 
bleeding, requiring a monthly hormone-free interval is unnecessary. For many women, 
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unnecessary bleeding episodes is desirable. Continuous or extended use of combined 
contraceptives is evidence-based practice and should be offered as an option to all 
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Table 1. Combined oral contraceptives approved for extended and continuous regimens 
Active ingredients and 
daily dosage 
Brand Name  Generic Names Regimen 
Levonorgestrel 
150mcg/ethinyl 











30 mcg tablets and  
ethinyl estradiol 10 
mcg tablets 
Seasonique  Amethia, 
Camrese 
84 active pills/7 low-




20 mcg and ethinyl 
estradiol 10 mcg 
tablets 
LoSeasonique  Amethia Lo, 
Camrese Lo 
84 active pills/7 low-




20 mcg tablets  
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Box 1. Key points for counseling women considering extended and continuous use 
combined contraceptive regimens 
• Preventing ovulation is the primary mechanism of action of all combined 
contraceptive regimens (cyclic, extended, and continuous) 
• Monthly bleeding episodes with combined contraceptives are not menses but 
instead are withdrawal bleeding designed to mimic the timing of normal 
menstrual cycles 
• There is no scientific evidence that monthly bleeding while on combined 
contraceptives is necessary 
• Extended and continuous use of combined contraceptives reduce and eliminate 
monthly withdrawal bleeding respectively; this is an expected outcome of these 
regimens and does not represent pathology 
• Menstrual blood does not “build up” with extended or continuous use of 
combined contraceptives; the endometrium is atrophic with all combined 
contraceptive regimens  
• Unpredictable breakthrough bleeding may occur with extended or continuous use 
of combined contraceptives; this is similar to cyclic regimens 
• No harmful effects have been documented specific to extended and continuous 
regimens; risks are similar to those with cyclic use 
• Fertility will return on discontinuation of extended and continuous regimens as it 
does with cyclic contraceptive use 
• Extended and continuous regimens can treat menses-related conditions and 
reduce contraceptive side effects 
• Women may find having fewer or no menses more convenient 
• Contraceptive costs may be higher with extended and continuous regimens, but 
less sanitary products will be needed 
• Provide a detailed schedule for the selected regimen, especially when hormone-
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